



Attorney Docket No.: 10084.000-US

03-56-03
PATENT
OW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chris Pernell

Confirmation No: 8839

Serial No.: 09/636,453

Group Art Unit: 1761

Filed: August 11, 2000

Examiner: Wong, L

For: Whey Protein Emulsion

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. CH 495 707 A
2. US 1 085 380 A
3. Patent Abstract Of Japan, Vol. 1995, No. 6 (JP 07 079699)
4. EP 1 020 120 A
5. US 5 993 862
6. WO 97 35485
7. US 4 515 825
8. US 5 308 628
9. US 3 357 838
10. US 6 190 724 B1
11. US 5 972 393 A

COPY OF PAPERS
ORIGINAL FILED
RECEIVED
FEB 26 2002
TC 1700

It is respectfully requested that these references be considered by the Patent and


Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed **after** the period set forth in 37 CFR 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the statement as specified in 37 C.F.R. § 1.97(e).

Respectfully submitted,

Date: February 5, 2002



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123